1
|
Taniguchi H, Rätsep I, Heinsar S, Liu K, Cespedes M, Suen JY, Li Bassi G, Fraser JF, Jacobs JP, Peek GJ. Iliopsoas haematoma during extracorporeal membrane oxygenation: A registry report from the COVID-19 critical care consortium across 30 countries. Perfusion 2023:2676591231168285. [PMID: 36988317 PMCID: PMC10064192 DOI: 10.1177/02676591231168285] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/30/2023]
Abstract
INTRODUCTION Iliopsoas haematoma (IPH) during extracorporeal membrane oxygenation (ECMO) is a rare bleeding complication that can be fatal due to its progression to abdominal compartment syndrome, but its incidence and risk factors are not well known. We have previously reported an IPH incidence rate of 16% in Japan. Among possible reasons for this high incidence, ethnicity has been hypothesised to play a role. Therefore, we used an international multi-centre cohort registry to test this hypothesis by determining the incidence rate of IPH. METHODS This study was performed using the COVID-19 Critical Care Consortium database, conducted in 30 countries across five continents between 3 January 2020, and 20 June 2022. RESULTS Overall, 1102 patients received ECMO for COVID-19-related acute respiratory distress syndrome. Of them, only seven were reported to have IPH, indicating an incidence rate of 0.64%, with comparable rates between the countries. The IPH group tended to have a higher mortality rate (71.4%) than the non-IPH group (51%). CONCLUSIONS Overall incidence of IPH in the studied COVID-19 ECMO cohort was 0.64%. Most cases were reported from Japan, Belgium, and Italy. In our study, this rare complication did not appear to be confined to Asian patients. Due to the high fatality rate, awareness about the occurrence of IPH should be recognised.
Collapse
Affiliation(s)
- Hayato Taniguchi
- Advanced Critical Care and Emergency Centre, Yokohama City University Medical Centre, Yokohama, Japan
| | - Indrek Rätsep
- Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Rode Road, Chermside, QLD, Australia
- Department of Intensive Care, North Estonia Medical Center, Tallinn, Estonia
| | - Silver Heinsar
- Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Rode Road, Chermside, QLD, Australia
- Department of Intensive Care, North Estonia Medical Center, Tallinn, Estonia
| | - Keibun Liu
- Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Rode Road, Chermside, QLD, Australia
| | - Marcela Cespedes
- Australian eHealth Research Centre, The Commonwealth Scientific and Industrial Research Organisation Surgical Treatment and Rehabilitation Service, Herston, QLD, Australia
- University of Queensland, Brisbane, QLD, Australia
| | - Jacky Y Suen
- Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Rode Road, Chermside, QLD, Australia
| | - Gianluigi Li Bassi
- Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Rode Road, Chermside, QLD, Australia
- University of Queensland, Brisbane, QLD, Australia
- Queensland University of Technology, Brisbane, QLD, Australia
- St Andrew’s War Memorial Hospital, Spring Hill, Australia
- Wesley Medical Research, Brisbane, QLD, Australia
| | - John F Fraser
- Critical Care Research Group, The Prince Charles Hospital and The University of Queensland, Rode Road, Chermside, QLD, Australia
| | - Jeffrey P Jacobs
- Congenital Heart Center, Shands Children’s Hospital, University of Florida, Gainesville, FL, USA
| | - Giles J Peek
- Congenital Heart Center, Shands Children’s Hospital, University of Florida, Gainesville, FL, USA
| |
Collapse
|
2
|
Hashemi H, Moradi H, Hashemi M, Naderi Z, Jafarpisheh S. Retroperitoneal hematoma in patients with COVID-19 infection during anticoagulant therapy: A case series and literature review. J Int Med Res 2022; 50:3000605221119662. [PMID: 36076361 PMCID: PMC9465591 DOI: 10.1177/03000605221119662] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Due to the hypercoagulable status of patients with severe COVID-19 infection,
anticoagulants are often used to prevent thrombosis. However, these agents may
cause bleeding events such as retroperitoneal hematoma (RPH). We report here on
six patients with COVID-19 who developed RPH during treatment. Early evidence of
bleeding led to confirmatory diagnosis with imaging. Four patients recovered
with supportive treatment (IV fluids and blood transfusions) and two patients
recovered by angioembolization. RPH should be considered in COVID patients on
anticoagulants as soon as haemoglobin or blood pressure falls. Further studies
are required to provide guidance and recommendations on use of anticoagulants in
critically ill patients with COVID-19.
Collapse
Affiliation(s)
- Huriyeh Hashemi
- Department of Internal Medicine, Isfahan University of Medical Science, Isfahan, Iran
| | - Hazhir Moradi
- Isfahan Students Research Committee, Medical School, Isfahan University of Medical Science, Isfahan, Iran
| | - Marzieh Hashemi
- Department of Internal Medicine, Isfahan University of Medical Science, Isfahan, Iran
| | - Zohre Naderi
- Department of Internal Medicine, Isfahan University of Medical Science, Isfahan, Iran
| | - Saleh Jafarpisheh
- Department of Radiology, Isfahan University of Medical Sciences, Isfahan, Iran
| |
Collapse
|
3
|
Park YM, Yoo JR, Chang WB. Multiple Surgical Treatments for Recurrent Retroperitoneal Hemorrhage in a COVID-19 Patient with Respiratory Failure on Extracorporeal Membrane Oxygenation. JOURNAL OF ACUTE CARE SURGERY 2022. [DOI: 10.17479/jacs.2022.12.2.77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Extracorporeal membrane oxygenation (ECMO) may be required in patients with corona virus disease-19 (COVID-19) and respiratory failure. Anticoagulation is the standard treatment to prevent complications of ECMO and COVID-19 coagulopathy, however, there is a risk of bleeding. Some patients with retroperitoneal hemorrhage (RPH) have been treated with angiography-embolization. We report on a patient with COVID-19 on ECMO who underwent multiple operations (×5) for recurrent RPH. A 46-year-old man was admitted with COVID-19 pneumonia. ECMO with anticoagulation therapy was initiated. The patient developed RPH, caused by external compression of the inferior vena cava interrupting the ECMO inflow, and surgical hematoma evacuation was performed, with no obvious bleeding focus during the multiple surgeries. Following the patient’s recovery, a follow-up computed tomography scan showed the hematoma had been resolved, but there was a dilemma regarding anticoagulation. Lowering the threshold for surgical treatment, enabled treatment of a patient with serious RPH.
Collapse
|